GLEN MILLS, PA -- June 7, 2005

Longport, Inc. (OTC BB: LPTI) a medical technology specialist in high resolution ultrasound imaging, today announced that it has signed a distribution agreement with Maximum Medical Inc, of Savanna, GA. Maximum Medical is an established medical marketing, sales, and service company specializing in wound care that has a sales force of more than 35 sales representatives operating from their offices in Orlando, FL, Savanna, GA, Dallas, TX, and Houston, TX. (See www.maxmed-usa.com)

Initially, Maximum Medical has placed an order for six demonstration EPISCAN systems and are expected to require an additional two demonstration units in the third quarter of 2005 as they roll out their EPISCAN sales and marketing program. Maximum Medical will be launching this program at the Wound Ostomy and Continence Nurses Society (WOCN) 37th Annual Conference in Las Vegas, between June 12th and 16th. This congress is expected to attract some 4,000 delegates. Longport staff will be supporting Maximum Medical at the WOCN Conference.

John Calabrese, Director of Sales and Marketing with Longport, said, "We believe this will be a very profitable relationship for both companies, and one that gives Longport greater market penetration. Maximum Medical is an established supplier of medical devices to clinics, hospitals, and nursing homes, and we will benefit from their existing relationships as well as the strength of the sales team in developing new business."

Greg Stewart, National Director of Sales and Operations with Maximum Medical, said, "We believe the addition of Longport's EPISCAN I-200 to our current product line truly makes us a total wound care and prevention company that promotes better patient care to our customer base. Welcome to the future of wound care!"

About Longport, Inc.
Longport, Inc. of Glen Mills, Pennsylvania, is a medical technology company that specializes in high resolution ultrasound imaging. After several years and a multi-million dollar investment in the technology, Longport has secured patents, copyrights and FDA permission to market. The Company's technology has been used to engineer a unique high resolution ultrasound imaging system. For further information please contact Longport, Inc. at 1-800-289-6863 or visit our website at www.longportinc.com

Forward-looking Information and the Private Securities Litigation Reform Act of 1995
Certain statements in this press release, including statements concerning product development milestones and anticipated events, are "forward-looking statements" within the Private Litigation Reform Act of 1995. Forward Looking Statements are based on the opinions and estimates of management at the time the statements are made and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect Longport's actual results include, among others, uncertainties as to the Company's ability to manage potential problems, delays or anticipated expenses, including problems, delays or expenses involving manufacturing. Readers are cautioned not to place undue reliance upon these forward-looking statements that speak only to the date of this release. Reference is made to Longport's 2003 annual report on Form 10-K filed with the Securities and Exchange Commission for a more definitive description of such factors. Longport, Inc. undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.